Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Value, Access & Devolved Nations, Merck Sharp and Dohme (UK) Ltd, London, UK.
Res Synth Methods. 2022 Sep;13(5):573-584. doi: 10.1002/jrsm.1539. Epub 2022 Jan 10.
Randomised controlled trials of cancer treatments typically report progression free survival (PFS) and overall survival (OS) outcomes. Existing methods to synthesise evidence on PFS and OS either rely on the proportional hazards assumption or make parametric assumptions which may not capture the diverse survival curve shapes across studies and treatments. Furthermore, PFS and OS are not independent; OS is the sum of PFS and post-progression survival (PPS). Our aim was to develop a non-parametric approach for jointly synthesising evidence from published Kaplan-Meier survival curves of PFS and OS without assuming proportional hazards. Restricted mean survival times (RMST) are estimated by the area under the survival curves (AUCs) up to a restricted follow-up time. The correlation between AUCs due to the constraint that OS > PFS is estimated using bootstrap re-sampling. Network meta-analysis models are given for RMST for PFS and PPS and ensure that OS = PFS + PPS. Both additive and multiplicative network meta-analysis models are presented to obtain relative treatment effects as either differences or ratios of RMST. The methods are illustrated with a network meta-analysis of treatments for stage IIIA-N2 non-small cell lung cancer. The approach has implications for health economic models of cancer treatments, which require estimates of the mean time spent in the PFS and PPS health-states. The methods can be applied to a single time-to-event outcome, and so have wide applicability in any field where time-to-event outcomes are reported, the proportional hazards assumption is in doubt, and survival curve shapes differ across studies and interventions.
癌症治疗的随机对照试验通常报告无进展生存期 (PFS) 和总生存期 (OS) 结果。现有的综合 PFS 和 OS 证据的方法要么依赖于比例风险假设,要么进行参数假设,这些假设可能无法捕捉到不同研究和治疗中的各种生存曲线形状。此外,PFS 和 OS 并不独立;OS 是 PFS 和进展后生存 (PPS) 的总和。我们的目的是开发一种非参数方法,用于综合发表的 PFS 和 OS 的 Kaplan-Meier 生存曲线的证据,而无需假设比例风险。受限平均生存时间 (RMST) 通过生存曲线下的面积 (AUC) 来估计,直至受限随访时间。由于 OS > PFS 的约束,AUC 之间的相关性使用 bootstrap 重采样进行估计。为 PFS 和 PPS 提供了 RMST 的网络荟萃分析模型,并确保 OS = PFS + PPS。同时呈现了加法和乘法网络荟萃分析模型,以获得作为 RMST 差异或比值的相对治疗效果。该方法通过对 IIIA-N2 期非小细胞肺癌治疗的网络荟萃分析进行了说明。该方法对癌症治疗的健康经济模型有影响,需要估计 PFS 和 PPS 健康状态下花费的平均时间。该方法可应用于单个时间到事件结果,因此在报告时间到事件结果、比例风险假设存在疑问以及生存曲线形状因研究和干预而异的任何领域都具有广泛的适用性。